Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
Open Access
- 25 January 2007
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 21 (3) , 489-493
- https://doi.org/10.1038/sj.leu.2404554
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood, 2006
- High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapyBlood, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatmentBlood, 2005
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Imatinib mesylate‐sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two casesAmerican Journal of Hematology, 2004
- Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatographyLeukemia, 2004
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001